1. Home
  2. SPRO vs WALD Comparison

SPRO vs WALD Comparison

Compare SPRO & WALD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.20

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Logo Waldencast plc

WALD

Waldencast plc

HOLD

Current Price

$1.63

Market Cap

179.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
WALD
Founded
2013
1988
Country
United States
United Kingdom
Employees
N/A
364
Industry
Biotechnology: Pharmaceutical Preparations
Package Goods/Cosmetics
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
156.3M
179.6M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SPRO
WALD
Price
$2.20
$1.63
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.00
AVG Volume (30 Days)
1.6M
660.1K
Earning Date
05-13-2026
03-13-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
N/A
Revenue This Year
N/A
$9.89
Revenue Next Year
$300.00
$4.31
P/E Ratio
N/A
N/A
Revenue Growth
39.24
N/A
52 Week Low
$1.80
$0.72
52 Week High
$3.09
$3.22

Technical Indicators

Market Signals
Indicator
SPRO
WALD
Relative Strength Index (RSI) 36.21 52.11
Support Level $2.19 $1.51
Resistance Level $2.47 $1.95
Average True Range (ATR) 0.26 0.21
MACD -0.07 -0.02
Stochastic Oscillator 22.29 53.33

Price Performance

Historical Comparison
SPRO
WALD

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About WALD Waldencast plc

Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.

Share on Social Networks: